India's dual pricing pressures

Share this article:

India is struggling to keep its export drug business an enriching one. The Economic Times reports that international customers are aware of what the companies are charging in-country and now want similar prices for themselves. The Economic Times says companies are concerned that price parity would threaten their businesses, since India's price controls have driven prices down 60% for what the government considers essential medicines.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.